148043-73-6

4,4,5,5,5-Pentafluoro-1-pentanol (PFP) is an essential building block primarily used in the commercial manufacture of the API. It is typically activated with a sulfonate leaving group and displaced selectively by the sulfur atom in 9-mercapto-1-nonanol to make 9-[(4,4,5,5,5-pentafluoropentyl)-thio]-1-nonanol (FVS). FVS is subsequently converted into a bromide and coupled with the steroid portion to make fulvestrant. First approved by the FDA in 2002, fulvestrant is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression.

Colorless to yellow liquid

An intermediate in the preparation of pentafluoropentane-1-thiol: an important chain of anti-breast cancer agents.

Pentafluoroiodoethane could used as a starting material to synthesize 4,4,5,5,5-Pentafluoro-1-pentanol. Specific steps are as follows: under an inert gas atmosphere, iron acetylacetonate, 6,6'-dimethyl-2,2'-bipyridine, and 1,2-dichloroethane were added to the reactor, reacted at RT for 0.5 h; added allyl alcohol, cesium carbonate, pentafluoroiodoethane successively, triisopropylsilane, warmed up to 80 ℃ and reacted for 24 h. Sampling and detection confirmed that the reaction of allyl alcohol was complete, stopped the reaction, and cooled to room temperature. The excess pentafluoroiodoethane was recovered, nitrogen was introduced into the system, hydrochloric acid was added to quench the reaction, washed, separated to obtain an organic phase, distilled to remove the solvent, and rectified to obtain 4,4,5,5,5-pentafluoro Amyl alcohol. Yield: 90.4%.